Literature DB >> 11469517

Monitoring the disease activity.

K Asmussen1.   

Abstract

Primary Sjögren's syndrome is a chronic systemic rheumatic disease characterized as an autoimmune exocrinopathy or autoimmune epithelitis thereby suggesting a pathogenesis leading to tissue specific autoimmune lesion. The development of internationally approved criteria for the classification and diagnosis of Sjögren's syndrome has been a major scientific task for nearly two decades with consensus now approaching. In contrast, an international dialogue on how to develop additional common criteria for the assessment of disease activity, organ damage and outcome in Sjögren's syndrome has just recently been initiated. Such assessment criteria would provide useful measures for patient management and are mandatory for comparing efficacy between different clinical trials. The lack of common assessment criteria may be explained by missing uniform diagnostic criteria, by the multispeciality and systemic nature of the disease and the difficulties in separating out what is activity and what is damage in Sjögren's syndrome. Attempts are now made to overcome these problems. The purpose of this paper is to give a brief introduction to the concepts of disease activity, damage and outcome in Sjogren's syndrome with reference to the results obtained from a recent workshop on assessment tools in Sjögren's syndrome held in Oxford, England in March 2000.

Entities:  

Mesh:

Year:  2001        PMID: 11469517     DOI: 10.1080/030097401300232600

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  2 in total

Review 1.  Effect of inflammation on lacrimal gland function.

Authors:  Driss Zoukhri
Journal:  Exp Eye Res       Date:  2005-11-23       Impact factor: 3.467

2.  Discovery of putative salivary biomarkers for Sjögren's syndrome using high resolution mass spectrometry and bioinformatics.

Authors:  Driss Zoukhri; Ian Rawe; Mabi Singh; Ashley Brown; Claire L Kublin; Kevin Dawson; William F Haddon; Earl L White; Kathleen M Hanley; Daniel Tusé; Wasyl Malyj; Athena Papas
Journal:  J Oral Sci       Date:  2012-03       Impact factor: 1.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.